Ivacaftor (VX-770)

Catalog No.S1144

Ivacaftor (VX-770) Chemical Structure

Molecular Weight(MW): 392.49

Ivacaftor (VX-770) is a selective potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM in fisher rat thyroid cells, respectively.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 14 Publications

7 Customer Reviews

  • (A) CFTR Western blot of normal (NL) and CF HBE cultures treated with VX-809 (5 uM) ± VX-770 (5 uM) for 48 hours. “*” indicates the mature, complex glycosylated form of CFTR, band C; “•” indicates the immature band B. (B) Turnover of rescued ΔF508 in BHK-21 cells. ΔF508 was rescued at 27°C in the presence of VX-809 ± VX-770 for 24 hours. After adding cycloheximide (200 ug/ml, 37°C), cells were lysed at the indicated times and analyzed by Western blotting.

    Sci Transl Med 2014 6(246), 246ra96. Ivacaftor (VX-770) purchased from Selleck.

  •  

    (A) Representative traces of Ca2+ mobilization induced by 100 μm of OAG after modulation of CFTR activity with 10 μm VX-770. (B) Histograms show normalized AUC corresponding to Ca2+ mobilization induced by 100 μm OAG (n, number of cells recorded/N, number of cell passages).

    Ivacaftor (VX-770) purchased from Selleck.

  •  

    (C) Representative traces of iodide efflux curves after CFTR stimulation with 10 μm VX-770 or 100μm OAG. (D) Histograms show the mean relative rate of CFTR activity for the experimental condition indicated below each bar (n = 4).

    Ivacaftor (VX-770) purchased from Selleck.

  • Treatment with DF508 CFTR correcting drugs (VX-770 and VX-809, 10 lM) partially redistributed F-actin in the submembrane compartment as also shown by the two small membrane peaks in the quantification graph. Treatment with PP2 (1 lM) alone or in combination with VX-770 and VX-809 completely recovered the actin distribution in DF508-chol similar to Control-chol. Phalloidin fluorescence intensity confirms the presence of membrane sharper peaks that reach intensity values comparable to Control-chol. Abbreviations: A.U, arbitrary units; chol, cholangiocytes.

    Hepatology, 2018, 67(3):972-988. Ivacaftor (VX-770) purchased from Selleck.

  • (A, B) Liquid absorption (Jv) was assessed in expanded alveolar epithelial cells from WT pigs under basal conditions (A) or following treatment with forskolin+IBMX (5+50 μmol/L, B) in the absence or presence of 10 μmol/L ivacaftor. n=10 transwells from 3 pigs.

    Crit Care Med, 2017, 45(12):e1240-e1246. Ivacaftor (VX-770) purchased from Selleck.

  • All curves in the presence of 50 μMforskolin. (A) VX-770, EC50 = 441 nM± 144, nH = 0.82 ± 0.2, n = 3 wells from one experiment.

    Br J Pharmacol, 2017, 174(7):525-539. Ivacaftor (VX-770) purchased from Selleck.

  • Mol Pharmacol, 2018, doi: 10.1124/mol.118.112177. Ivacaftor (VX-770) purchased from Selleck.

Purity & Quality Control

Choose Selective CFTR Inhibitors

Biological Activity

Description Ivacaftor (VX-770) is a selective potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM in fisher rat thyroid cells, respectively.
Features The first potent and orally available CFTR potentiator to enter human clinical trials.
Targets
F508del-CFTR [1]
(Fisher rat thyroid cells)
G551D-CFTR [1]
(Fisher rat thyroid cells)
25 nM(EC50) 100 nM(EC50)
In vitro

Ivacaftor (10 μM) significantly increases the forskolin-stimulated Cl- secretion (IT) by ~4-fold with an EC50 of 100 nM in the recombinant Fisher rat thyroid (FRT) cells expressing G551D gating mutation of CFTR, and by ~6-fold with an EC50 of 25 nM in the recombinant cells expressing temperature-corrected F508del processing mutation of CFTR. Consistent with the increases in the forskolin-stimulated IT, Ivacaftor (10 μM) increases the open probability (Po) of G551D-, F508del-, and wild-type CFTR by ~6-fold, ~5-fold and ~2-fold, respectively, indicating that Ivacaftor acts directly on CFTR to increase its gating activity. In primary cultured human CF bronchial epithelia (HBE) carrying the G551D and F508del CFTR mutations, Ivacaftor (10 μM) potently increases the forskolin-stimulated IT by ~10-fold from 5% to a maximum level of 48% of that measured in non-CF HBE, with an EC50 of 236 nM displaying ~70-fold more potency compared with the commonly used CFTR potentiator genistein, which has an EC50 of 16 μM. In HBE with F508del homozygous CFTR, Ivacaftor causes a significant increase in the forskolin-stimulated IT with an EC50 of 22 nM, to a less extent from 4% to 16% of non-CF HBE compared with the effect in G551D/F508del HBE. Due to CFTR potentiation, Ivacaftor inhibits excessive ENaC-mediated Na+ and fluid absorption with an IC50 of 43 nM, and decreases the amiloride response, resulting in an increase in the surface fluid and cilia beat frequency (CBF) in G551D/F508del HBE. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HBE  NGPwNG5HfW6ldHnvckBCe3OjeR?= NYLuUm5KOTBizszN M{DUUFExKG2rbh?= MVLheYdu\W62czDDSnRTNWSncHXu[IVvfCCrb36geJJidnOyb4L0xsA> MXSyOFExPjhyMR?=
CFBE41o- NHvtd2JHfW6ldHnvckBCe3OjeR?= M3HLb|ExKML3TR?= M3jnN4lv\HWlZYOgdo9jfXO2IHnuZ5Jm[XOnczDpckBidmmxbjD0doFve3CxcoS= NWfD[GJ6OjJ5NkixN|A>
HBE  NHPKcGFHfW6ldHnvckBCe3OjeR?= NUL4PGFKOTBiwsXN M3LYd4F2\22nboTzJGNHXFJvZHXw[Y5l\W62IHHubY9vKHS{YX7zdI9zfCCjY4Tpeol1gQ>? MmPHNlI4PjhzM{C=
HBE  NFX3Nm9HfW6ldHnvckBCe3OjeR?= NUDyN|RFOTBiwsXN NWHsZlM1OjRiaB?= MYTpcoR2[2W|IHGgcY9l\XO2IHL1eEB{cWewaX\pZ4FvfCCrbnPy[YF{\SCrbjDBV2wh\GWydHi= NF\UVVQzOjd4OEGzNC=>
HBE  M{TuVWZ2dmO2aX;uJGF{e2G7 MXOxNEDDvU1? Mlm3dI91\W62aXH0[ZMhS0[WUj3k[ZBmdmSnboSgTZNkNCC{ZXfhdoRt\XO|IH;mJJBzcW:{IHHkcYlvcXO2cnH0bY9vKG:oIFPTSS=> MnfKNlI4PjhzM{C=
HBE  MV;GeY5kfGmxbjDBd5NigQ>? MU[xNEDDvU1? M1vnbJBienSrYXzsfUBz\XO2b4Lld{Bl\XCuZYTpc44hd2ZiQWPMJIRmeHSqIHnuJGNUTSC2cnXheIVlKG2xbn;sZZlmenN? MYWyNlc3QDF|MB?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PPARγ / pERK; 

PubMed: 30498130     


Caco-2 cells incubated with P31–43 in the presence or absence of VX-770. Immunoblot of PPARc or phospho-ERK1/2 (phERK1/2) and densitometric analysis of protein levels relative to b-actin.

NLRP3; 

PubMed: 30498130     


Immunoblotting with specific antibodies (NLRP3) in Caco-2 cells challenged for 2 or 4 h in the presence or absence of VX-770. NLRP3 expression.

Rδf508; 

PubMed: 25101887     


Effect of VX-770 on the expression pattern of low temperature-rescued ΔF508-CFTR-3HA determined by immunoblot. Cells were treated with VX-770 alone for 24 hours at 26°C. CFTR was visualized with anti-HA antibody, and anti–Na+/K+-ATPase antibody served as loading control. 

30498130 25101887
Immunofluorescence
F-actin; 

PubMed: 30498130     


Confocal image staining with anti-F-actin. DAPI (blue), nuclear counterstaining. Scale bar, 50 μm.

30498130

Protocol

Solubility (25°C)

In vitro DMSO 78 mg/mL (198.73 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 392.49
Formula

C24H28N2O3

CAS No. 873054-44-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03251911 Not yet recruiting Chronic Bronchitis University of Alabama at Birmingham January 1 2020 Phase 4
NCT03251911 Not yet recruiting Chronic Bronchitis University of Alabama at Birmingham January 1 2020 Phase 4
NCT03439865 Not yet recruiting Chronic Rhinosinusitis (Diagnosis) University of Alabama at Birmingham|National Heart Lung and Blood Institute (NHLBI) July 2019 Early Phase 1
NCT03439865 Not yet recruiting Chronic Rhinosinusitis (Diagnosis) University of Alabama at Birmingham|National Heart Lung and Blood Institute (NHLBI) July 2019 Early Phase 1
NCT03783286 Recruiting Cystic Fibrosis Children''s Hospital of Philadelphia|Vertex Pharmaceuticals Incorporated February 6 2019 --
NCT03783286 Recruiting Cystic Fibrosis Children''s Hospital of Philadelphia|Vertex Pharmaceuticals Incorporated February 6 2019 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CFTR Signaling Pathway Map

Related CFTR Products0

Tags: buy Ivacaftor (VX-770) | Ivacaftor (VX-770) ic50 | Ivacaftor (VX-770) price | Ivacaftor (VX-770) cost | Ivacaftor (VX-770) solubility dmso | Ivacaftor (VX-770) purchase | Ivacaftor (VX-770) manufacturer | Ivacaftor (VX-770) research buy | Ivacaftor (VX-770) order | Ivacaftor (VX-770) mouse | Ivacaftor (VX-770) chemical structure | Ivacaftor (VX-770) mw | Ivacaftor (VX-770) molecular weight | Ivacaftor (VX-770) datasheet | Ivacaftor (VX-770) supplier | Ivacaftor (VX-770) in vitro | Ivacaftor (VX-770) cell line | Ivacaftor (VX-770) concentration | Ivacaftor (VX-770) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID